Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
Media: UCB and @Amgen announce positive vote from @US_FDA advisory committee for potential new #osteoporosis treatment https://t.co/roadh9Rbr1 https://t.co/6h0m6D9l0g
— UCB News (@ucb_news) 17.01.2019 -
UCB has been converting science into solutions since 1928. #UCB90 https://t.co/u4PldAzlHa https://t.co/2JF0vIbfIs
— UCB News (@ucb_news) 16.01.2019 -
Dedicating your talent to push the boundaries of what is possible for patients today – that is what working at UCB is all about. #UCB90 https://t.co/xnfUepMf3Z
— UCB News (@ucb_news) 15.01.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
